A proof-of-concept study of a microdose of latanoprost 0.005% showed positive results, according to a press release from Eyenovia.
The EYN PG21 study evaluated 60 eyes of 30 healthy volunteers who received one microdose of piezo-print latanoprost each day for 2 consecutive days. Drug administration volume was reduced by 75%, as the dose was accurately and directly administered to the corneal surface, the release said. In addition, diurnal IOP was reduced up to 29% from baseline unmedicated IOP, which is consistent with standard latanoprost drops.
“We believe these compelling results

Full Story →

A proof-of-concept study of a microdose of latanoprost 0.005% showed positive results, according to a press release from Eyenovia.
The EYN PG21 study evaluated 60 eyes of 30 healthy volunteers who received one microdose of piezo-print latanoprost each day for 2 consecutive days. Drug administration volume was reduced by 75%, as the dose was accurately and directly administered to the corneal surface, the release said. In addition, diurnal IOP was reduced up to 29% from baseline unmedicated IOP, which is consistent with standard latanoprost drops.
“We believe these compelling results

Full Story →